Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)

NCT05219630 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05219630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05219630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 16, 2022
Completion date
May 30, 2023
Enrollment
106 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive